HGF in Conversation: Andrew Tindall on the IP Landscape of Personalised Medicine

How is the convergence of genomics, AI, diagnostics and gene therapies reshaping healthcare, and what does this mean for intellectual property?

Andrew Tindall, Patent Director at HGF, recently joined Parola Analytics for an in-depth discussion on the evolving patent landscape of personalised medicine. In the interview, Andrew shares his perspective on how patent strategies have adapted over the last decade, the growing importance of biomarkers and data exclusivity, and the IP challenges that arise as biotechnology, healthcare and digital technologies increasingly intersect.

Read the full article here.

The article forms part of Parola Analytics’ analysis of innovation trends in personalised medicine and explores both global patent activity and the practical IP considerations facing companies operating in this rapidly developing field.

As personalised medicine continues to evolve, securing the right IP strategy is becoming increasingly important. Drawing on HGF’s deep expertise in the life sciences sector, we help businesses protect, develop and commercialise innovation at the intersection of healthcare, biotechnology and digital technologies.

If you’d like to discuss the IP challenges and opportunities arising from personalised medicine, please get in touch with a member of HGF’s Life Sciences team.